Its announcement will come around the heels of the same licensing arrangement provided in February to Adastra Labs, which had until now focused on crafting cannabis extracts. Adastra's license also permits it to make and market psilocybin and psilocin – hallucinogens far more usually generally known as magic mushrooms that make consequences much